Medical Oncologist
Understanding your treatment
How Long Does Sunitinib — Take to Work?
Sunitinib does not produce an immediate visible change. The first formal measurement of whether it is working comes from a scan, usually ordered after one or two treatment cycles — roughly 8 to 12 weeks in.
Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed August 2026
- No immediate signal — You cannot tell from how you feel in the first weeks whether sunitinib is working. That is normal.
- First scan at 8–12 weeks — Your oncologist will order imaging after one or two cycles to assess the tumour's response.
- Stable disease is a success — The tumour not growing is a meaningful outcome — shrinkage is not the only measure of response.
- Side effects are not failure — Side effects tell you the drug is in your system. They do not tell you what it is doing to the tumour.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Sunitinib does not produce an immediate change you can feel. The first formal assessment of whether it is working usually happens at 8 to 12 weeks, via a scan. In the weeks before that, the drug is active in your body — but results are measured on imaging, not on day-to-day symptoms.
What happens week by week on sunitinib?
Weeks 1–2: The drug builds up in your system
Sunitinib reaches steady levels in the blood within the first two weeks. You may notice early side effects — fatigue, a change in taste, or mild nausea — as the drug becomes active. These are signs the drug is in your system, not signs of how the tumour is responding.
Weeks 3–4: End of the first on-treatment phase
On the standard four-weeks-on, two-weeks-off schedule, you complete your first active cycle here. Side effects may be at their most noticeable during this period. Your team is watching for any early problems; this is not yet the point where tumour response is formally measured.
Weeks 5–6: Your two-week break
The scheduled break allows side effects to settle — hand-foot syndrome, fatigue and mouth soreness typically improve during these weeks. The break is part of the treatment design, not a rest from the drug's activity. Many patients feel noticeably better in this window.
Weeks 7–10: Second cycle begins
Your second active cycle starts. Your oncologist is building a picture of how your body tolerates the drug over two cycles before ordering formal response imaging.
Weeks 8–12: First response scan
Most oncologists order the first imaging assessment — usually a CT scan — after one or two completed cycles. NCCN guidance recommends response assessment at this point. The scan compares the tumour now against your baseline scan from the start of treatment. This is the first formal measurement of whether the drug is working.
Does feeling worse mean sunitinib is not working?
Side effects and tumour response are separate things. Sunitinib's side effects — fatigue, hand-foot syndrome, nausea, changes in blood pressure — reflect the drug acting on your body. They do not tell you what it is doing to the tumour.
Some patients feel worse in the first weeks while their tumour is shrinking. Some feel relatively well while the disease continues to grow. This is why the scan matters — it is the only reliable measure.
If side effects are making daily life very difficult, tell your team. Dose adjustments are a standard part of sunitinib management and can reduce the burden without necessarily reducing the drug's effect on the tumour.
What does it mean if the tumour has not shrunk?
Stable disease — where the tumour has not grown — is a meaningful and intended outcome with sunitinib. NCCN and ESMO both include stable disease as a valid treatment response, not a failure.
Sunitinib is primarily anti-angiogenic: it aims to cut off the tumour's blood supply and slow its growth, rather than always producing rapid shrinkage. Stopping growth for a sustained period is what the treatment is designed to achieve.
If your scan shows the tumour has grown since starting treatment, your oncologist will discuss what the next step is. That conversation is different from, and much more important than, whether the tumour has shrunk.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
What do the scan results actually mean?
- Complete response
- No detectable tumour visible on imaging. This is uncommon with sunitinib and not the primary goal of treatment.
- Partial response
- The tumour has become measurably smaller. According to RECIST criteria used in oncology, this means a meaningful reduction in the sum of target lesion measurements.
- Stable disease
- The tumour has not grown beyond the threshold that would classify it as progression, and has not shrunk enough to classify as a response. This is a good outcome with sunitinib.
- Progressive disease
- The tumour has grown beyond the threshold set by RECIST criteria, or new lesions have appeared. This means the current treatment is not controlling the cancer.
- RECIST
- Response Evaluation Criteria in Solid Tumours — the international standard used to measure whether a solid tumour has responded to treatment on a scan.
What should you track while waiting for your scan?
- Note any new symptoms, or a clear worsening of existing symptoms, and report these to your team rather than waiting for your next appointment.
- Keep a daily record of side effects — fatigue level, any skin changes on palms or soles, mouth soreness, and blood pressure if you have a home monitor.
- Tell your team about all other medicines you are taking, including supplements and herbal preparations — several interact with sunitinib.
- Do not stop taking sunitinib because you feel unwell without speaking to your team first. A dose adjustment is usually the right step, not stopping.
- Attend all scheduled blood test appointments — kidney function, liver function and blood counts are monitored throughout, not just at scan time.
- Ask your team before your scan what they will be measuring, so you understand the result when it comes.
What happens after the first scan?
Your oncologist will compare the scan against your baseline images and give you a clear result using standard RECIST criteria. You should expect a direct conversation about what the result means for your treatment.
If the scan shows response or stable disease, treatment usually continues with the same dose or a reviewed dose if side effects have been significant. Subsequent scans are ordered at intervals your oncologist will specify.
If the scan shows progression, your oncologist will discuss alternatives. For the cancers where sunitinib is used, there are usually further options available. Ask when you will hear — not whether you will hear.
Explore 75 more Kidney, Ovarian & Sarcoma Targeted Medicines topics
Drug Deep Dive: Sunitinib (Sutent)
- Diet and Nutrition While on Sunitinib
- Drug, Food and Supplement Interactions With Sunitinib
- Fertility, Pregnancy and Contraception on Sunitinib
- Hand-Foot Skin Reaction on Sunitinib: Prevention From Day One
- How Does Sunitinib Work? The Multi-Kinase Angiogenesis Inhibitor Explained
- How Long Does Sunitinib Take to Work?
- How Long Will You Stay on Sunitinib?
- Mouth Sores, Taste Loss and Yellow Skin Discolouration on Sunitinib
- Sunitinib (Sutent, Sunitix): The Complete Patient Guide
- Sunitinib After Kidney Surgery and for GIST: Two Different Settings
- Sunitinib Myths: Hair Colour Change, Dose Cuts and 'Weaker Treatment'
- Sunitinib Price in India: Brand, Generic and Monthly Cost
- Sunitinib Side Effects: The Complete List and Timeline
- Sunitinib Success Rate and Survival: An Honest Look at the Numbers
- Sunitinib and Immunotherapy: Where Combinations Fit in Kidney Cancer
- Sunitinib in Elderly Patients and Those With Other Illnesses
- Sunitinib vs Pazopanib vs Cabozantinib for Kidney Cancer
- Taking Sunitinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Sunitinib
- The 4-Weeks-On, 2-Weeks-Off Sunitinib Schedule and the 2/1 Alternative
- Thyroid Failure and Fatigue on Sunitinib: The Test to Repeat Every Cycle
- When Sunitinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Sunitinib? Kidney Cancer, GIST and Pancreatic Neuroendocrine Tumours
- Will Insurance or a Government Scheme Pay for Sunitinib?
- Work, Travel and Daily Life on Sunitinib
Drug Deep Dive: Olaparib (Lynparza)
- Adjuvant Olaparib After Early Breast Cancer Surgery
- Anaemia and Extreme Fatigue on Olaparib
- Blood Cancer Risk After Long-Term Olaparib: How Real Is It?
- Diet and Nutrition While on Olaparib
- Drug, Food and Supplement Interactions With Olaparib
- Fertility, Pregnancy and Contraception on Olaparib
- How Does Olaparib Work? The PARP Inhibitor Explained
- How Long Does Olaparib Take to Work?
- How Long Will You Stay on Olaparib?
- Maintenance Olaparib: Taking a Drug When There Is No Visible Cancer
- Nausea on Olaparib: Managing the Most Common Side Effect
- Olaparib (Lynparza, Olanib): The Complete Patient Guide
- Olaparib Myths: 'Only for BRCA', 'It's Chemo', 'It Causes Cancer'
- Olaparib Price in India: Brand, Generic and Monthly Cost
- Olaparib Side Effects: The Complete List and Timeline
- Olaparib Success Rate and Survival: An Honest Look at the Numbers
- Olaparib With Bevacizumab or Hormone Therapy: Combination Regimens
- Olaparib in Elderly Patients and Those With Other Illnesses
- Olaparib vs Niraparib vs Talazoparib: Comparing PARP Inhibitors
- Taking Olaparib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Olaparib
- When Olaparib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Olaparib? BRCA-Mutated Ovarian, Breast, Prostate and Pancreatic Cancer
- Will Insurance or a Government Scheme Pay for Olaparib?
- Work, Travel and Daily Life on Olaparib
Drug Deep Dive: Pazopanib (Votrient)
- Diarrhoea and Blood Pressure Rise on Pazopanib
- Diet and Nutrition While on Pazopanib
- Drug, Food and Supplement Interactions With Pazopanib
- Fertility, Pregnancy and Contraception on Pazopanib
- Hair Turning White and Skin Lightening on Pazopanib
- How Does Pazopanib Work? The Multi-Kinase Angiogenesis Inhibitor Explained
- How Long Does Pazopanib Take to Work?
- How Long Will You Stay on Pazopanib?
- Liver Toxicity on Pazopanib: Why LFTs Are Checked Every Two Weeks
- Pazopanib (Votrient, Pazonib): The Complete Patient Guide
- Pazopanib Combinations: Why It Is Usually Given Alone
- Pazopanib Myths: Hair Colour, Liver Damage and Stopping Early
- Pazopanib Price in India: Brand, Generic and Monthly Cost
- Pazopanib Side Effects: The Complete List and Timeline
- Pazopanib Success Rate and Survival: An Honest Look at the Numbers
- Pazopanib for Soft Tissue Sarcoma: What It Can and Cannot Do
- Pazopanib in Elderly Patients and Those With Other Illnesses
- Pazopanib in Kidney Cancer vs Sarcoma: Two Different Treatment Goals
- Pazopanib vs Sunitinib: Comparing Toxicity and Quality of Life
- Taking Pazopanib on an Empty Stomach: Why the Timing Rule Exists
- Tests and Monitoring While You Are on Pazopanib
- When Pazopanib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Pazopanib? Kidney Cancer and Soft Tissue Sarcoma
- Will Insurance or a Government Scheme Pay for Pazopanib?
- Work, Travel and Daily Life on Pazopanib
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Can I tell if sunitinib is working from how I feel?
Not reliably. How you feel during treatment reflects the drug's side effects on your body, not what it is doing to the tumour. Some patients feel significant fatigue while their tumour is shrinking; others feel relatively well while the disease progresses. The only reliable signal is the scan. If you notice new pain, new swelling, or a clear deterioration in a symptom that was related to your cancer before treatment, tell your team — that is worth reporting separately from routine side effects.
How many cycles does it take before we know if sunitinib is working?
Most oncologists order the first formal response scan after one or two cycles — roughly 8 to 12 weeks into treatment. NCCN guidance supports this timeline. In practice, the decision depends on your cancer type, your baseline scan findings, and how you are tolerating the drug. Ask your oncologist specifically when your first assessment scan is planned, so you have a clear date to wait for rather than an open-ended uncertainty.
What if the tumour has not shrunk on the first scan?
Stable disease — the tumour not growing — is a recognised and valid treatment outcome with sunitinib. NCCN and ESMO include it as a response category, not a failure. Sunitinib is designed primarily to slow tumour growth by cutting off its blood supply, not necessarily to cause rapid shrinkage. Your oncologist will interpret the result in the context of your specific cancer and give you a clear picture of what it means for continuing treatment.
Is it normal to feel worse when starting sunitinib?
Yes. Fatigue, nausea, hand-foot syndrome and changes in taste are common in the first weeks and can make this period feel discouraging. Most of these side effects peak during the on-treatment weeks and improve during the two-week break. Feeling worse in this period does not mean the treatment is failing — it means your body is adjusting to a drug with a real pharmacological effect. If side effects are severe or getting worse rather than manageable, contact your team: dose adjustments are standard and can make a significant difference.
Does the two-week break mean the drug stops working?
No. The four-weeks-on, two-weeks-off schedule is the treatment design, not a gap in therapy. The break gives your body time to recover from side effects, which makes it possible to continue treatment over many months. Sunitinib's effects on the tumour's blood supply are not immediately reversed during the break. The schedule was established in clinical trials precisely because it sustains patients on treatment for longer than a continuous daily dose would allow.
What questions should I ask before my first scan?
Ask three things: when exactly the scan is scheduled, what your oncologist will be measuring and comparing it against, and what the possible outcomes are and what each would mean for your treatment. Getting clear answers before the scan means you spend less of the waiting period in uncertainty, and you understand the result when it comes without having to process new information and new implications at the same time.